This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Mar;6(1):1-2.

doi: 10.1007/s11899-010-0072-8.

Should patients with low-risk myelodysplastic syndrome be treated earlier in the course of their disease?

Eric J Feldman¹

Affiliations

PMID: 21161616
DOI: 10.1007/s11899-010-0072-8

Comment

Should patients with low-risk myelodysplastic syndrome be treated earlier in the course of their disease?

Eric J Feldman. Curr Hematol Malig Rep. 2011 Mar.

. 2011 Mar;6(1):1-2.

doi: 10.1007/s11899-010-0072-8.

Author

Eric J Feldman¹

Affiliation

¹ Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA. ejf2001@med.cornell.edu

PMID: 21161616
DOI: 10.1007/s11899-010-0072-8

No abstract available

PubMed Disclaimer

Comment on

Cause of death in patients with lower-risk myelodysplastic syndrome.
Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Dayyani F, et al. Cancer. 2010 May 1;116(9):2174-9. doi: 10.1002/cncr.24984. Cancer. 2010. PMID: 20162709 Free PMC article.

References

1. J Clin Oncol. 2002 May 15;20(10):2429-40 - PubMed
1. Cancer. 2006 Apr 15;106(8):1794-803 - PubMed
1. Lancet Oncol. 2009 Mar;10(3):223-32 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Springer